Trial Profile
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2012
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Canagliflozin/metformin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 31 Jan 2012 New trial record